Loading…
← CockpitCompetitor Analysis › MLYS Mineralys Therapeutics, Inc.Open in the cockpit ↗

Mineralys Therapeutics, Inc.MLYSCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops lorundrostat, an oral aldosterone synthase inhibitor, for treatment-resistant hypertension.

Momentum laggard 6
Mkt cap
$1.22B
US dollars, full cap
Free float
69%
of shares outstanding
$/day
$34.9M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 8.9%
Hurdle
n/a
no reverse DCF
Next earnings
120 days
18 Mar 2027
Close · USD$13.78
1D-4.8%
1W-14.7%
1M-36.1%
3M-46.5%
6M-51.5%
YTD-62.0%
1Y-68.9%
ATR %9.4%
Beta1.62
52w lowhigh69.4% off high

What Mineralys Therapeutics does

Develops lorundrostat, an oral aldosterone synthase inhibitor, for treatment-resistant hypertension.

Has no approved product and no sales; funding comes from raising capital, and everything rides on one drug, lorundrostat, through late-stage trials and regulatory review. Hypertension is dominated by cheap generics, so a new pill must earn its place with doctors and insurers.

Products and services

  • Lorundrostat (resistant/uncontrolled hypertension)

Customers

  • Cardiologists/primary care (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Hypertension therapeutics

What could go right

  • Large resistant hypertension market
  • Potential first-to-market advantage

What could go wrong

  • Competitive race with AstraZeneca's baxdrostat
  • Clinical and regulatory timeline risk

Moat: none (IP / patents). Differentiated aldosterone synthase mechanism but competes directly with a similar AstraZeneca candidate.

Headquarters: Radnor, Pennsylvania, US · Founded: 2018 · Employees: 76

Named competitors

Mineralys Therapeutics at a glance

Size Mineralys Therapeutics (MLYS) is a United States Health Care company (Biotechnology) with a market value of $1.22B, the 2107th largest of 3,085 United States companies the cockpit tracks. Shares closed at $13.78 on 18 Nov 2026.

Performance Over six months the shares fell 51.5%, against -21.1% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 19 in its peer set.

Short interest Short interest is 8.7% of the free float (30 Oct 2026).

Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 78MLYS 46
Six months, rebased to 100: Mineralys Therapeutics against the median of its 20 peers (local-currency closes).

Mineralys Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$30,000-$59,000-$43,000$0$0
EBITDA-$390M-$171M-$192M-$84.7M-$31.5M
Net income-$370M-$155M-$178M-$71.9M-$29.8M
Free cash flow-$153M-$142M-$166M-$81.2M-$29.2M
Capital expenditure$15,000$15,000$96,000$0$0
Total debt$98.3M$0$0$0$0

Quarterly statements and history in the cockpit →

Mineralys Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-50%0%+50%688739AKUMS000403301207CMPSNVAXNUVBTYRAVOR4588JBIO9606MLYS6-month return →1-month return →
Up and to the right = strong over both horizons. Mineralys Therapeutics is the large dot.

Mineralys Therapeutics competitors and peer comparison

Head to head with its named competitors (MLYS vs AZN.L vs IDIA.SW)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Mineralys Therapeutics MLYS$1.22B-52%n/an/an/an/a
AstraZeneca AZN.L$278B-2%+5%23%5.0×14.4%
Idorsia IDIA.SW$1.22B-9%-5%-70%10.4×n/a

How Mineralys Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Mineralys Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureMLYSPeer medianRank in peer set
1-month return-36.1%-12.5%2nd lowest of 21
6-month return-51.5%-21.1%2nd lowest of 19
Distance from 52-week high-69.4%-48.0%2nd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Mineralys Therapeutics MLYSUnited States$1.22B-52%n/an/an/an/an/a
Liaoning Chengda Biotechnology 688739.SSChina$1.22B-14%-9%0%2.2×6.6%-7.0%
Akums Drugs and Pharmaceuticals AKUMS.NSIndia$1.21B+38%+18%10%2.0×15.3%+9.9%
Pacific Shuanglin Bio-pharmacy 000403.SZChina$1.24B-21%+1%10%3.5×n/an/a
Hualan Biological Vaccine 301207.SZChina$1.25B-29%-28%-7%9.0×33.2%-13.1%
Kardigan KARDUnited States$1.15Bn/an/an/an/an/an/a
COMPASS Pathways Plc Sponsored ADR CMPSUnited States$1.15B-25%n/an/an/an/an/a
Taysha Gene Therapies TSHAUnited States$1.30B-27%-13%-2,998%170.1×n/an/a
Novavax NVAXUnited States$1.31B-14%-61%-17%2.4×n/an/a
Zhuhai Trinomab Pharmaceutical 688806.SSChina$1.32Bn/a+238%-1,196%164.8×n/an/a
Nuvation Bio NUVBUnited States$1.34B-16%+654%-61%5.7×n/an/a
Generate Biomedicines GENBUnited States$1.34B-20%+56%-737%31.7×n/an/a
Tyra Bioscience TYRAUnited States$1.35B-41%n/an/an/an/an/a
Vor Biopharma VORUnited States$1.10B+15%n/an/an/an/an/a
CanSino Biologics 6185.HKHong Kong$1.36B-23%+36%-4%6.8×n/an/a
Intellia Therapeutics NTLAUnited States$1.37B-20%-8%-821%21.3×n/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%408.9×n/an/a
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%50.1×n/an/a
Jade Biosciences JBIOUnited States$1.07B-34%n/an/an/an/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%7.9×0.5%+25.6%
Duality Biotherapeutics 9606.HKHong Kong$1.06B-58%-5%-181%5.6×n/an/a

Questions

Who are Mineralys Therapeutics's main competitors?
Named competitors: AstraZeneca (baxdrostat) (AZN.L), Idorsia (IDIA.SW). The cockpit's measured peer set (industry) also includes Liaoning Chengda Biotechnology (688739.SS), Akums Drugs and Pharmaceuticals (AKUMS.NS), Pacific Shuanglin Bio-pharmacy (000403.SZ), Hualan Biological Vaccine (301207.SZ), Kardigan (KARD), COMPASS Pathways Plc Sponsored ADR (CMPS).
How has Mineralys Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -51.5% against -21.1% for the median peer; over one year -68.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.